Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR is a depositary receipt listed on the NYSE for Novo Nordisk A/S, a Denmark-based pharmaceutical company founded in 1923 and headquartered in Bagsvaerd. Through its subsidiaries, the company researches, develops, manufactures, and distributes medicines across two reportable segments: Obesity and Diabetes Care, and Rare Disease. Its portfolio includes treatments for diabetes, obesity, cardiovascular and other emerging therapy areas, as well as products for rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Novo Nordisk also markets devices and digital tools such as NovoPen 6, NovoPen Echo Plus, Dose Check, growth hormone pens, and injection needles, and it offers Wegovy pill, an oral GLP-1 receptor agonist therapy for weight management. The company operates across Europe, North America, Asia Pacific, Latin America, the Middle East, and Africa, and it has collaborations with Anthropic and Orbis Medicines.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-NVO
$61.55
47.8% Upside
Undervalued
$45.50
9.3% Upside
Fair
Great
3.2%
February 3, 2027
10.9x
5.6x
3.7x
181 B
199.4 B
9.9%
71.6%
7.1
45.9%
63.3%
Valuation • Fair Value

Novo Nordisk A/S ADR (NYSE-NVO) Fair Value by Valuation Model

Review the available estimates for Novo Nordisk A/S ADR (NYSE-NVO), including DCF Fair Value, Ben Graham Formula Value, DDM Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$61.55

Estimated upside of 47.8% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$64.15

Discounted cash flow valuation reference.

Ben Graham Formula Value

$42.11

Classic Ben Graham valuation formula reference.

DDM Fair Value

$60.29

Dividend discount model valuation reference.

EPV Fair Value

$61.92

Earnings power value estimate.

Comps Fair Value

$59.08

Comparable-company valuation reference.

Analyst Price Target

$45.50

Analysts imply upside of 9.3%.

How to read these valuation models

Use the 8 available valuation references for Novo Nordisk A/S ADR (NYSE-NVO) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Novo Nordisk A/S ADR (NYSE-NVO)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

50.55 B

Current operating scale indicator.

Revenue Forecast

45.105 B

Forward revenue estimate.

EBITDA

27.506 B

Current operating profitability reference.

EBITDA Forecast

22.409 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Novo Nordisk A/S ADR (NYSE-NVO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Novo Nordisk A/S ADR (NYSE-NVO)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.36

No elevated caution signal from this screen.

Altman Z-Score

7.1

Relatively strong balance-sheet zone.

FCF / Net Income

63.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Novo Nordisk A/S ADR (NYSE-NVO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Novo Nordisk A/S ADR (NYSE-NVO)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

February 3, 2027

Days to Earnings

82

Dividend Yield

3.2%

Current income yield reference.

Payout Ratio

45.9%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Novo Nordisk A/S ADR (NYSE-NVO), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Novo Nordisk A/S ADR (NYSE-NVO) Stock Forecast & Technical Outlook

Review Novo Nordisk A/S ADR (NYSE-NVO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Novo Nordisk A/S ADR (NYSE-NVO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Novo Nordisk A/S ADR (NYSE-NVO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Novo Nordisk A/S ADR (NYSE-NVO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Novo Nordisk A/S ADR (NYSE-NVO) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Novo Nordisk A/S ADR (NYSE-NVO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Novo Nordisk A/S ADR (NYSE-NVO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Novo Nordisk A/S ADR (NYSE-NVO) has a Hold consensus, with 3 buy, 10 hold and 1 sell recommendations in the current data set.

Buy 3
Hold 10
Sell 1
FAQ • Fast Investor Answers

Novo Nordisk A/S ADR (NYSE-NVO) Stock FAQ

Data-supported answers about Novo Nordisk A/S ADR (NYSE-NVO), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$61.55
Estimated upside 47.8%
Valuation Rating
Undervalued
Estimated upside of 47.8%
Analyst Target
$45.50
Implied upside 9.3%
Financial Health
Great
Current financial-health read

The current fair value estimate for Novo Nordisk A/S ADR (NYSE-NVO) is $61.55. This implies an estimated upside of 47.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 47.8% versus the current market price.

The available analyst price target for Novo Nordisk A/S ADR (NYSE-NVO) is $45.50. The analyst target implies estimated upside of 9.3%.

The current financial health read for Novo Nordisk A/S ADR (NYSE-NVO) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Novo Nordisk A/S ADR (NYSE-NVO) is February 3, 2027.

Based on the current data, dividend yield is 3.2%.

The current P/E ratio listed for Novo Nordisk A/S ADR (NYSE-NVO) is 10.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Novo Nordisk A/S ADR is 181 B.

The current enterprise value listed for Novo Nordisk A/S ADR is 199.4 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Novo Nordisk A/S ADR is NYSE-NVO, and the stock is listed on NYSE.

Novo Nordisk A/S ADR (NYSE-NVO) is listed on NYSE.

The current debt-to-total-capital ratio listed for Novo Nordisk A/S ADR is 9.9%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Novo Nordisk A/S ADR is 71.6%. Free float helps investors understand how much of the share base is available for public trading.